UNSPSC 51402206: Duloxetine hydrochloride

This classification denotes an antidepressant agent with the molecular formula C18H19NOS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9044SC542W, chemically known as 5-chloro-1-(1-(3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro-2h-benzimidazol-2-one but more generally known as duloxetine hydrochloride, which bears US NIH Compound Identifier 3151. European Medicines Agency schedules Duloxetine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20026.

UNSPSC 51402206 Duloxetine hydrochloride is a Commodity code that nominally identifies a specific antidepressant pharmaceutical product, yet the recent state and local opportunities tagged to this code show minimal relevant activity. The three most recent solicitations under this code address naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS Commission), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these opportunities specifically procure duloxetine hydrochloride or narrow to this branded product; instead, they represent broader pharmaceutical supply, cooperative purchasing arrangements, and pharmacy benefit program redesign. The code appears to have been applied incorrectly or as a catch-all taxonomy marker rather than in the specific product sense its eight-digit commodity designation implies.

Issuing bodies using this code span state health agencies, county health departments, and cooperative purchasing vehicles. Seminole County, Florida posted an IFB for naloxone and drug deactivation systems with a response deadline of July 26, 2023 (note: this date predates the posting date and represents a data inconsistency in the source). The Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs, framed as market intelligence rather than a binding procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP posted January 20, 2026 with a response deadline of March 26, 2026 for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions. Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state membership extending the practical geography. Given the mismatch between the code's narrow product scope and the broad pharmaceutical-procurement opportunities surfacing under it, this code shows little targeted recent activity for duloxetine hydrochloride specifically.